QSAM Biosciences Opens Enrollment of the Second Cohort of Patients in its Phase 1 Study of CycloSam Targeting Metastatic Bone Cancer

Austin, TX, April 05, 2023 (GLOBE NEWSWIRE) — QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam), for the treatment of bone cancer and other diseases and conditions, today announces the opening of enrollment into the 2 grouping of participants (Cohort 2) after completing Cohort 1 in February in its Phase 1 study evaluating CycloSam in the treatment of bone cancer. “We have met all criteria to continue patient enrollment at a higher dose level in the next group of patients,” stated Douglas R. Baum, CEO. “We are pleased with the safety data and…